Literature DB >> 11588109

Beneficial effects of the Ca2+ sensitizer EMD 57033 in exercising pigs with infarction-induced chronic left ventricular dysfunction.

D J Duncker1, D B Haitsma, D A Liem, N Heins, R Stubenitsky, P D Verdouw.   

Abstract

1. It is unknown how cardiac stimulation by Ca(2+) sensitization modulates the cardiovascular response to exercise when left ventricular (LV) function is chronically depressed following a myocardial infarction. We therefore investigated the effects of EMD 57033 at rest and during exercise and compared these to those of the mixed Ca(2+)-sensitizer/phosphodiesterase-III inhibitor pimobendan. 2. Pigs were chronically instrumented for measurement of cardiovascular performance. At the time of instrumentation, infarction was produced by coronary artery ligation (MI, n=12). Studies in MI were performed in the awake state, 2 - 3 weeks after infarction. 3. MI were characterized by a lower resting cardiac output (18%), stroke volume (30%) and LVdP/dt(max) (18%), and a doubling of LV end-diastolic pressure, compared to normal pigs (N, n=13). 4. In 11 resting MI, intravenous EMD 57033 (0.2 - 0.8 mg kg(-1) min(-1)) increased LVdP/dt(max) (57+/-5%) and stroke volume (26+/-6%) with no effect on heart rate, LV filling pressure, and myocardial O(2)-consumption, similar to N. 5. In MI, the effects of EMD 57033 (0.4 mg kg(-1) min(-1), IV) on stroke volume and LVdP/dt(max) were maintained during treadmill exercise up to 85% of maximal heart rate, while heart rate was lower compared to control exercise (all P<0.05). In contrast, the effects of EMD57033 gradually waned in N at increasing intensity of exercise. 6. Compared to N, the cardiostimulatory effects of pimobendan (20 microg kg(-1) min(-1), IV) were blunted in MI both at rest and during exercise compared to N. 7. In conclusion, the positive inotropic actions of the Ca(2+) sensitizer EMD 57033 are unmitigated in resting and exercising MI compared to N, while those of the mixed Ca(2+)-sensitizer/phosphodiesterase-III inhibitor pimobendan are blunted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588109      PMCID: PMC1572986          DOI: 10.1038/sj.bjp.0704292

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure.

Authors:  N Ohte; C P Cheng; M Suzuki; W C Little
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

2.  Ca++ sensitizers impair cardiac relaxation in failing human myocardium.

Authors:  R J Hajjar; U Schmidt; P Helm; J K Gwathmey
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

Review 3.  Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.

Authors:  S H Kubo
Journal:  Cardiology       Date:  1997       Impact factor: 1.869

4.  Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.

Authors:  J Lilleberg; S Sundberg; M S Nieminen
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

5.  Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy.

Authors:  P S Pagel; M F McGough; D A Hettrick; D Lowe; J P Tessmer; I N Jamali; D C Warltier
Journal:  J Cardiovasc Pharmacol       Date:  1997-05       Impact factor: 3.105

6.  Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.

Authors:  H Takaoka; M Takeuchi; K Hata; Y Hayashi; M Mori; H Yamakawa; K Yamaguchi; M Yokoyama
Journal:  Am Heart J       Date:  1997-03       Impact factor: 4.749

7.  Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dog.

Authors:  S Teramura; T Yamakado; M Maeda; T Nakano
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

8.  Effects of levosimendan on myocardial contractility and oxygen consumption.

Authors:  K Todaka; J Wang; G H Yi; R Stennett; M Knecht; M Packer; D Burkhoff
Journal:  J Pharmacol Exp Ther       Date:  1996-10       Impact factor: 4.030

9.  Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.

Authors:  E Udvary; J G Papp; A Végh
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 10.  Phosphodiesterase inhibition and Ca2+ sensitization.

Authors:  U Ravens; H M Himmel; M Flüss; K Davia; S E Harding
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

View more
  1 in total

Review 1.  'Integrative Physiology 2.0': integration of systems biology into physiology and its application to cardiovascular homeostasis.

Authors:  Diederik W D Kuster; Daphne Merkus; Jolanda van der Velden; Adrie J M Verhoeven; Dirk J Duncker
Journal:  J Physiol       Date:  2011-01-04       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.